MARIETTA, Ga., Aug. 1, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it will present at the 37th Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, Christopher M. Cashman, EVP & Chief Commercialization Officer and Mark Landy, VP-Strategic Initiatives, are scheduled to present on Wednesday, August 9, 2017 at 12:30 p.m. eastern time, at the InterContinental Boston. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx® is a biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of placental tissue, having supplied over 900,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.
SOURCE MiMedx Group, Inc.